T
here has been a dramatic increase in the use of bioprosthetic valves in patients undergoing aortic valve replacement (AVR), with this valve type accounting for ≈80% of all implanted prostheses in the recent years. 1, 2 The major benefit of bioprosthetic valves is the avoidance of long-term anticoagulation, which leads to a lower cumulative risk of bleeding and thromboembolic events. Their Achilles' heel remains the anticipated structural valve deterioration, particularly in younger patients who may require multiple reinterventions. 3 With the advent of transcatheter aortic valve replacement (TAVR), failing prosthetic aortic valves are often replaced percutaneously, with a valve-in-valve (VIV) approach. 4, 5 However, long-term durability of VIV TAVR remains unknown, and poor early outcomes have been reported, particularly in cases of small bioprosthetic valves at risk for patient-prosthesis mismatch (PPM). 4, 6 PPM after AVR increases all-cause and cardiac-related long-term mortality. [7] [8] [9] An adequate prosthetic valve size should match patients' body size to allow proper blood flow and promote left ventricular mass regression. 10 , 11 Pibarot et al 12, 13 proposed a classification of PPM severity according to the valve's effective orifice area indexed by patients' body surface area (BSA), with severe PPM categorized as an indexed effective orifice area (EOAi) <0.65 cm 2 /m 2 . Several groups have reported that an EOAi <0.85 cm 2 /m 2 is associated with worse hemodynamic and clinical outcomes after AVR. 14, 15 Surgical aortic root enlargement (ARE) during AVR allows for larger prosthesis implantation, thus minimizing PPM. 10, 11, [16] [17] [18] Furthermore, ARE may also benefit individuals who undergo a VIV TAVR in the future by allowing deployment of a larger percutaneous valve. Despite these potential benefits, surgical ARE has not been widely adopted by cardiac surgeons, likely because of concerns regarding the possible increased risk of early mortality and morbidity. Small single-center studies have reported acceptable results in patients undergoing aortic root enlargement at the time of AVR. [19] [20] [21] [22] [23] However, there is a paucity of data comparing early outcomes between AVR+ARE and AVR alone. We therefore conducted a retrospective cohort study with the objective of comparing early outcomes and determining the incremental risk of adding aortic root enlargement to AVR.
METHODS

Data Sources and Study Outcomes
This observational, single-center, cohort study was approved by the Review Ethics Board of University Health Network (Toronto, Ontario, Canada), and a waiver of consent was obtained. Patient-level data will not be made available to other researchers for the purposes of reproducing the results of this study because of privacy concerns. However, analytical methods and aggregate data are reported in the manuscript and the online-only Data Supplement. Perioperative clinical data were prospectively collected on all patients undergoing cardiac surgery in our institutional database. The primary outcome of this study was in-hospital mortality. Secondary outcomes of interest included postoperative adverse events, including acute myocardial infarction, low cardiac output, permanent pacemaker implantation, infection, atrial fibrillation, transient ischemic attack/stroke, reoperation for bleeding, and renal failure. All outcomes of interest were reported according to the American Association for Thoracic Surgery Guidelines for Reporting Mortality and Morbidity Mortality After Cardiac Valve Interventions. 24 
Study Population
All patients who underwent aortic valve replacement at the Toronto General Hospital, Peter Munk Cardiac Center from January 1990 to August 2014 were identified through the cardiovascular surgical database. Patients who underwent aortic valve replacement were included in the AVR group, and those who underwent AVR with a root enlargement were included in the AVR+ARE group. Operative reports were manually reviewed to confirm the technique of aortic root enlargement in the AVR+ARE group. Patients in the AVR+ARE group included all patients who had any form of aortic root or annular enlargement, including: (1) aortic root enlargement with replacement of the noncoronary sinus with a patch allowing for supraannular implantation of the valve ( Figure 2B ), which extends the aortotomy through the nadir of the noncoronary sinus to the aortic annulus, has been used regularly by our surgeons. We also regularly use the Nunez modification of the Manouguian technique 26 ( Figure 2A ). This technique extends the aortotomy through the commissure between the noncoronary and left cusps (the same direction as in the original Manouguian technique) to just above the confluence of the interventricular fibrous trigone, left atrial wall, and mitral valve
Clinical Perspective
What Is New?
• This is the first large-scale study that examines the incremental risk of surgical aortic root enlargement in patients undergoing aortic valve replacement.
• We observed no incremental risk in postoperative mortality or adverse events after surgical enlargement of the aortic root compared with aortic valve replacement alone.
What Are the Clinical Implications?
• Patients with a small aortic annulus at risk for patient-prosthesis mismatch and those who may require transcatheter redo aortic valve replacement in the future may benefit from surgical enlargement of the aortic root.
• Surgical aortic root enlargement is a safe adjunct in the modern era and should be considered at the time of surgical aortic valve replacement.
annulus, thus avoiding injury to the mitral leaflet and reconstruction of the left atrial roof. We reserve the original Manouguian technique, 27 which includes opening the left atrial roof and incising the anterior leaflet of the mitral valve, for patients requiring mitral valve replacement or extensive reconstruction of the base of the heart. Twenty-two surgeons performed aortic root enlargement during the study period, and the decision to enlarge the root and the choice of technique were most often dictated by personal experience and preference for one technique over another. Certain patient and anatomic factors, such as how small the baseline annulus was and what degree of enlargement was necessary for a given patient, were also taken into consideration. Patients with aortic dissection and active endocarditis, and those undergoing a composite valve graft procedure or Ross procedure, were excluded from this study.
Statistical Analysis
Categorical variables were reported as frequencies, and continuous variables were reported as mean±standard deviation or median with interquartile ranges as appropriate. Patient and surgical characteristics were compared using unpaired t test, analysis of variance test (continuous variables), or χ . EOAi was calculated by determining the patient's implanted valve EOA (cm) as reported by Pibarot et al 13 and
Logistic regression was used to examine the association of ARE with in-hospital mortality and adverse events. Risk factor analysis was conducted using backward selection using the Akaike Information Criterion. 28 Separate models were considered for each primary and secondary outcome. Although all other clinical characteristics were subject to variable selection, 
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the independent variable of interest (ARE) was included in all models and not subject to variable selection. For our risk factor analysis, missing values were stochastically imputed using a multiple imputation method. A systemic search was conducted to exclude highly correlated risk factors. If 2 variables had a high Pearson correlation, the 1 with the largest average absolute correlation was removed from consideration. This procedure removed mean cardiopulmonary bypass time from the analysis because it was highly correlated with cross-clamp time. We conducted 3 prespecified subgroup analyses examining the effect of surgical aortic root enlargement in: (1) patients undergoing AVR alone (ie, without concomitant procedures), (2) patients undergoing AVR with bioprosthetic valves, and (3) patients undergoing ARE with a specific technique (annular enlargement versus noncoronary sinus patch enlargement). Propensity score matching was performed to account for potential bias arising from treatment selection. 29 We performed 1:1 greedy matching without replacement 30 on a propensity score calculated based on all baseline variables. As a means to ensure that each pair had exactly the same missing pattern, nearest neighbor matching with a widely used caliper width of 0.25 was used to match cases and controls. 31 To assess the performance of the matching, pre-and postmatching covariable imbalance between the comparison cohort as absolute standardized mean differences is reported. 29 Matched-adjusted results for the primary outcome were reported using matchpaired methods. Specifically, the effect of ARE was evaluated using McNemar's tests. In addition, to account for the residual imbalance, we used the generalized estimating equation 29, 32 to calculate the adjusted effect of surgical ARE.
Statistical significance was indicated throughout by a 2-tailed P value <0.05. All analyses were performed using the R project of Statistical Computing version 3.3.1.
RESULTS
Baseline Characteristics and Intraoperative Details
In all, 7039 consecutive patients underwent AVR during the study period, of whom 1854 (26%) underwent ARE with a pericardial patch and 5185 (74%) underwent AVR without ARE. Baseline characteristics of the study cohort are available in Table 1 . Mean age was 65±14 years and 37% were female. Important differences were noted in frequency of previous sternotomy, advanced New York Heart Association class, and urgent/ emergent status, which were higher in the AVR+ARE group. Mean BSA and frequency of bicuspid aortic valves were lower in the AVR+ARE group.
Operative Details
The operative techniques for ARE have been previously described, 20, 33 and operative details are reported in Figure 3 and Table 3 ). Rates of bioprosthetic valve implantation were similar between groups (AVR+ARE: 73.4% versus AVR: 73.3%, P=0.98). The postoperative EOAi for both AVR and AVR+ARE groups, stratified by the 4 most common aortic valve models implanted, is reported in Table 3 . As expected, patients undergoing AVR+ARE required longer cross-clamp (105±39 versus 92±35 minutes, P<0.001) and cardiopulmonary bypass times (133±49 versus 117±43 minutes, P<0.001).
In-Hospital Outcomes
The prevalence of in-hospital mortality for the entire cohort was 3.4%, and unadjusted mortality was higher after AVR with a root enlargement (AVR+ARE: 4.3% versus AVR: 3.0%, P=0.008). When concomitant cardiac procedures were excluded, mortality was not statistically different between the 2 groups (isolated AVR+ARE: 1.7% versus isolated AVR: 1.1%, P=0.28). The frequency of early complications was not statistically different between groups, with the exception of low cardiac output and permanent pacemaker implantation, which were higher after AVR+ARE (Table 4) . When concomitant procedures and redo operations were excluded, the rate of pacemaker implantation was lower and not statistically different between groups (AVR+ARE: 5.1% versus AVR: 5.5%, P=0.75).
Multivariable Analyses
After adjustment for potential confounders, aortic root enlargement was not associated with an increased risk of in-hospital mortality (odds ratio [OR], 1.03; 95% confidence interval [CI], 0.75-1.41; P=0.85). The complete logistic regression model for mortality is included in Table 5 . Figure 4 summarizes the association between surgical strategy and the outcomes of interest after adjusting for baseline differences between the 2 groups. Aortic root enlargement was not associated with any in-hospital adverse event.
Propensity Score Analysis
After propensity score matching, 88% of the root enlargement group was appropriately matched. 
Subgroup Analysis
When the analysis was restricted to patients having isolated AVR with or without surgical ARE, we found that aortic root enlargement was not associated with an increased risk of in-hospital mortality (OR, 1.58; 95% Values are n (%) or mean±SD. 27) . Similarly, when the analysis was restricted to patients receiving a bioprosthesis, we found that aortic root enlargement was not associated with an increased risk of in-hospital mortality (OR, 0.87; 95% CI, 0.59-1.27; P=0.47). Differences in patient characteristics and operative results between the 2 main surgical techniques used in this paper (annular enlargement versus noncoronary sinus patch enlargement) are reported in Table II in Figure I and II in the online-only Data Supplement. Neither surgical technique was associated with in-hospital mortality. When the 2 main techniques (annular enlargement versus noncoronary sinus repair) were compared directly, we found no difference in early outcomes apart from an increased risk of bleeding after noncoronary sinus repair (OR, 2.56; 95% CI, 1.45-4.59; P=0.001).
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DISCUSSION
The most important finding of this paper is that aortic root enlargement may be safely added to AVR without an increased risk of early mortality. Furthermore, the addition of ARE to AVR was not associated with an increased risk of postoperative adverse events. To our knowledge, this is the largest series reporting outcomes after aortic valve replacement with or without aortic root enlargement.
With the increasing use of VIV TAVR for failing bioprosthetic valves, the cardiovascular community has renewed interest in the role of ARE during conventional AVR. Worse outcomes after VIV TAVR have been reported in patients with small (≤21 mm) or intermediate (>21 and <25 mm) sized bioprostheses, those with surgical PPM, and those with postprocedural gradients of ≥20 mm Hg. [4] [5] [6] Because the use of biological valves is increasing dramatically, surgeons must consider the possibility of future VIV TAVR when implanting a biological valve in a young patient. ARE should be considered when the internal diameter of a specific valve model and size will be inadequate to achieve a good result with VIV TAVR. Some groups, including ours, have adopted an aggressive approach to the management of a small aortic annulus during AVR to increase the size of the implanted valve in an effort to minimize long-term adverse events and to facilitate future VIV TAVR. Several small single-center studies have presented acceptable results of ARE at the time of AVR, 16, [19] [20] [21] [22] [23] 34, 35 demonstrating the technique's feasibility. The incremental risk of adding ARE to AVR, however, has not been previously reported in a large series. Despite the longer cross-clamp and cardiopulmonary bypass times, ARE was not an independent predictor of early mortality or early adverse events.
Various techniques for implanting a larger aortic prosthesis have been described and were used throughout the study period to achieve a similar goal of inserting a larger prosthesis in the aortic valve position. When we examined the perioperative results stratified for the 2 main techniques used in this paper, we found no association with either annular enlargement or the noncoronary sinus patch technique with mortality. Annular enlargement was independently associated with an increased need for permanent pacemaker implantation. Several other strategies are available in the surgeon's armamentarium to address a small aortic root. Stentless aortic valves such as the Toronto SPV valve provide larger EOAi than stented bioprostheses. 36, 37 We no longer use these valves, however, given their limited durability and technical complexity at the time of reoperation. Contemporary options to avoid PPM include rapid deployment aortic valve bioprostheses and TAVI, which 
ORIGINAL RESEARCH ARTICLE
have also been shown to provide higher EOAi. 38, 39 We currently reserve both options for patients with significant comorbidities and lower life expectancy because their long-term durability is unknown.
Despite our aggressive management of a small aortic root at the time of AVR, mean EOAi in the AVR+ARE group was 0.82±0.15 cm 2 /m 2 and was smaller than the AVR group. We presume that the EOAi for patients undergoing AVR+ARE would have been even smaller without a root enlargement. The exact degree of enlargement obtained by these ARE techniques cannot be ascertained from these data and would require a prospective study. We use surgical ARE liberally, particularly in young and active patients with a high BSA who are at risk of mismatch or may return for VIV TAVR. We believe Hancock II to be more durable than currently available pericardial valves, 40, 41 but its hemodynamic performance is inferior. 42, 43 In patients where durability is an issue (patients 50-70 years of age), we favored this bioprosthesis with liberal use of root enlargement to avoid PPM. This partly accounts for the high proportion of the ARE group 686/1854 (37.0%) that had an implanted valve with a labeled size ≥25. In patients in whom PPM is likely (ie, small aortic root and high BSA), particularly those who are older (>70 years of age), we tend to favor pericardial valves that provide a larger postoperative EOAi.
LIMITATIONS
This is an analysis of a large cohort of patients undergoing aortic valve replacement with or without root enlargement with careful determination of all early morbidity and mortality. The main limitations of this study stem from its retrospective nature. Although multiple strategies were used to account for differences between the groups, we could not account for other potential unmeasured confounders. The decision regarding whether to enlarge the root, and the specific technique and patch material that was used, was at the discretion of the surgeon. Furthermore, this study reports the results from a single center where ARE is done 
